deltatrials

Non-small cell lung cancer Trials in Karlsruhe, Germany

Conditions / Non-small cell lung cancer / Karlsruhe, Germany

Non-small cell lung cancer has been the subject of sustained clinical investigation across multiple research sites.

16 total trials for this combination

Showing top 10 of 16 trials

Trials

NCT ID Title Status Phase
NCT00418886 Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients COMPLETED PHASE3
NCT06793215 A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer RECRUITING PHASE3
NCT00364351 Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy COMPLETED PHASE3
NCT01999673 Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer COMPLETED PHASE3
NCT01493843 Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without Pictilisib in Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer COMPLETED PHASE2
NCT00373425 A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors COMPLETED PHASE3
NCT05502237 Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer ACTIVE_NOT_RECRUITING PHASE3
NCT02619929 Initial Oral Vinorelbine Dosing Schedules in Clinical Routine in Germany and Austria COMPLETED
NCT02486718 Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010] ACTIVE_NOT_RECRUITING PHASE3
NCT06767514 Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1 RECRUITING PHASE3

Related Pages